CA Patent

CA2928286A1 — Solid form of ruxolitinib phosphate

Assigned to Signa SA de CV · Expires 2016-10-28 · 10y expired

What this patent protects

A solid, polymorphic form APO-I of Ruxolitinib phosphate is provided.

USPTO Abstract

A solid, polymorphic form APO-I of Ruxolitinib phosphate is provided.

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CA2928286A1
Jurisdiction: CA
Classification: —
Expires: 2016-10-28
Drug substance claim: No
Drug product claim: No
Assignee: Signa SA de CV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.